Who is sponsoring NCT06092047?

NCT06092047 is sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd..

What drugs are being tested in NCT06092047?

Interventions in NCT06092047: UTAA09 cells for infusion, Fludarabine, Cyclophosphamide.

What condition does NCT06092047 study?

NCT06092047 studies CD19-positive Relapsed or Refractory B-cell Malignancies.

Is NCT06092047 still recruiting?

NCT06092047 is currently recruiting now. Last updated 13 May 2025.

Last reviewed 2025-05-13 · How we verify

NCT06092047

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Universal Off-the-shelf Cell Products in Patients With CD19-positive Relapsed/Refractory B-cell Hematolymphatic Malignancies.

Recruiting now EARLY_PHASE1 Last updated 13 May 2025

What this trial tests

EARLY_PHASE1 trial testing UTAA09 cells for infusion in CD19-positive Relapsed or Refractory B-cell Malignancies in 10 participants. Currently enrolling.

Timeline

1 October 2023

Primary endpoint
1 July 2026

1 April 2028

Quick facts

Lead sponsor	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 October 2023
Primary completion	1 July 2026
Estimated completion	1 April 2028
Sites	1 location across China

Drugs / interventions tested

UTAA09 cells for infusion — full drug profile →
Fludarabine (FLUDARABINE) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

CD19-positive Relapsed or Refractory B-cell Malignancies — all drugs for CD19-positive Relapsed or Refractory B-cell Malignancies →

Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd. — full company profile →

Who can join

Adults 3 to 70, any sex, with CD19-positive Relapsed or Refractory B-cell Malignancies. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Assessment of the safety after UTAA09 injection treatment
Time frame: About 2 years
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
Evaluation of the efficacy after UTAA09 injection treatment
Time frame: About 3 months
3-month total response rate (ORR) which includes CR, CRi, and PR will be assessed.

Sponsor's own description

This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic malignancies.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Diverse Subsets of γδT Cells and Their Specific Functions Across Liver Diseases.
Zhan C, Peng C, Wei H, Wei K, et al · · 2025 · cited 4× · PMID 40141420 · DOI 10.3390/ijms26062778
Re-Tooling of γδ T Cells for Cancer Immunotherapy Using Advanced Manufacturing and Genetic Engineering.
Lim BJL, Maher J. · · 2026 · PMID 41892285 · DOI 10.3390/cells15060494
Commentary on "Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer".
de Bont DA, Straetemans T, Sebestyén Z, Kuball J. · · 2026 · PMID 41735001 · DOI 10.1136/jitc-2025-014199

Verify or expand the search:

Other PersonGen BioTherapeutics (Suzhou) Co., Ltd. trials

Trials by the same sponsor.

NCT07338604 — Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies · EARLY_PHASE1 · recruiting
NCT07284927 — Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies · Phase 1 · recruiting
NCT07312630 — Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign · EARLY_PHASE1 · recruiting
NCT07188610 — PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma · Phase 2 · recruiting
NCT06970951 — Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06092047 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Last refreshed: 13 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06092047.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing